We scan new podcasts and send you the top 5 insights daily.
Tom argues that if a patient is fit enough for cystectomy, they should be fit enough to start EV plus pembrolizumab, so the single-agent perioperative pembrolizumab scenario is mostly hypothetical in his view. The exception he describes is metastatic lymph-node-only disease with comorbidities, not curative-intent MIBC.
The success of neoadjuvant immunotherapy trials like Niagara and those with EV-Pembro means most patients will receive immune therapy before surgery. This fundamentally shifts the clinical landscape, making the question of starting adjuvant immunotherapy less relevant as perioperative treatment becomes the standard.
The transformative efficacy of EV-Pembro has ushered in a new, aggressive treatment philosophy for both muscle-invasive and metastatic bladder cancer. The approach is to administer the combination upfront to gain rapid disease control, and only then make subsequent decisions about surgery, radiation, or further therapy.
An expert would not offer just the adjuvant portion of the EV-Pembro regimen to a patient who went straight to surgery, even though the full perioperative (neoadjuvant + adjuvant) regimen is approved. This highlights a strict adherence to trial data, where the lack of specific evidence for a purely adjuvant application prevents off-label use.
Tom says he sees no big role for adjuvant immune therapy because waiting for neoadjuvant chemotherapy and cystectomy means many patients never reach that phase. He prefers early immune therapy, as in Niagara, because some patients are cured with neoadjuvant treatment. This sequencing argument favors perioperative IO over postoperative-only IO.
For elderly or frail patients with metastatic bladder cancer, treatment choice hinges on goals. Enfortumab vedotin (EV) monotherapy is preferred for a rapid response in symptomatic or bulky disease. In contrast, pembrolizumab monotherapy is better for a lower-intensity approach in patients with low-volume disease where durable benefit and quality of life are prioritized.
Tom says perioperative EV-pembrolizumab produced hazard ratios of 0.53 and 0.60 versus Niagara's 0.68 and 0.75, with path CR jumping to 55%. Rob still expects Niagara to remain relevant until EV is licensed and reimbursed in many countries. Access barriers, not just efficacy, shape near-term standard of care.
Tom reads the hazard ratios as a near-exact stepwise drop: 0.71 for pembrolizumab versus cystectomy and 0.40 for EV plus pembrolizumab, with each component apparently contributing about 0.3. He cautions the 85-patient arms are small, but says the EFS curves visually support this additive pattern.
Giving EV Pembro perioperatively for muscle-invasive bladder cancer provides the best chance for a cure. Waiting to use it in the first-line metastatic setting is a major gamble, as many patients relapse and may not get a second chance at effective therapy. The consensus is to use the best treatment upfront.
Expert consensus shows a major paradigm shift: perioperative systemic therapy (like EV-Pembro, scoring 2.9) is the undisputed standard for muscle-invasive bladder cancer. Approaches starting with cystectomy alone now score below 1.8, formally branding them as inferior options.
The success of EV-Pembro in perioperative trials has established it as a foundational treatment. The emerging clinical philosophy is to initiate EV-Pembro for a wide spectrum of muscle-invasive disease and then decide on subsequent steps, like surgery, based on the patient's response, marking a major strategic shift.